Wednesday, July 8, 2026

Drug profile · INN

talazoparib tosylate

talazoparib tosylate (TALZENNA) is a poly [adp-ribose] polymerase-1 inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 3
Pipeline programs 2
News articles 2
Drug details — talazoparib tosylate

Quick answer

talazoparib tosylate (TALZENNA) is a poly [adp-ribose] polymerase-1 inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN talazoparib tosylate
Brand TALZENNA
Mechanism Poly [ADP-ribose] polymerase-1 inhibitor
Target Poly [ADP-ribose] polymerase 2
Route ORAL
Formulation CAPSULE

Mechanism of action

Poly [ADP-ribose] polymerase-1 inhibitor

Primary target: Poly [ADP-ribose] polymerase 2

Approval history

Authority Status Date
FDA approved

Recent coverage

Pipeline programs

  1. Talazoparib Tosylate Phase 2 · BioMarin Pharmaceutical Australia · Advanced Breast Cancer
  2. Talazoparib Phase 1 · BioMarin Pharmaceutical Australia · Childhood Solid Tumors

Related & competitor drugs

  1. niraparib tosylate Poly [ADP-ribose] polymerase 2 inhibitor
  2. niraparib Antineoplastic and immunomodulating agents (L01)
  3. talazoparib Antineoplastic and immunomodulating agents (L01)
  4. niraparib tosilate hydrate Poly [ADP-ribose] polymerase 2 inhibitor
  5. talazoparib tosilate Poly [ADP-ribose] polymerase 2 inhibitor
  6. imp4297 Poly [ADP-ribose] polymerase 2 inhibitor

Related patents

  1. US 8735392

    Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt

    Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 8420650

    Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)

    Expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 8012976

    Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)

    Expires Mon Sep 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is talazoparib tosylate?

talazoparib tosylate (TALZENNA) is a poly [adp-ribose] polymerase-1 inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for talazoparib tosylate?

TALZENNA is a marketed brand name for talazoparib tosylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of talazoparib tosylate?

talazoparib tosylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.